| Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma A Scherpereel, P Astoul, P Baas, T Berghmans, H Clayson, P De Vuyst, ... European Respiratory Journal 35 (3), 479-495, 2010 | 770 | 2010 |
| Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma L Strizzi, A Catalano, G Vianale, S Orecchia, A Casalini, G Tassi, ... The Journal of pathology 193 (4), 468-475, 2001 | 473 | 2001 |
| Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial L Calabrò, A Morra, E Fonsatti, O Cutaia, G Amato, D Giannarelli, ... The Lancet Oncology 14 (11), 1104-1111, 2013 | 418 | 2013 |
| Simian virus 40, poliovaccines and human tumors: a review of recent developments M Carbone, P Rizzo, HI Pass Oncogene 15 (16), 1877-1888, 1997 | 235 | 1997 |
| ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma A Scherpereel, I Opitz, T Berghmans, I Psallidas, M Glatzer, D Rigau, ... European respiratory journal 55 (6), 2020 | 216 | 2020 |
| Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells M Fiorillo, R Lamb, HB Tanowitz, L Mutti, M Krstic-Demonacos, ... Oncotarget 7 (23), 34084, 2016 | 210 | 2016 |
| MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications S Busacca, S Germano, L De Cecco, M Rinaldi, F Comoglio, F Favero, ... American journal of respiratory cell and molecular biology 42 (3), 312-319, 2010 | 199 | 2010 |
| Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer A Cristaudo, R Foddis, A Vivaldi, G Guglielmi, N Dipalma, R Filiberti, ... Clinical Cancer Research 13 (17), 5076-5081, 2007 | 179 | 2007 |
| SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma P Cacciotti, R Libener, P Betta, F Martini, C Porta, A Procopio, L Strizzi, ... Proceedings of the National Academy of Sciences 98 (21), 12032-12037, 2001 | 177 | 2001 |
| Advances in the systemic therapy of malignant pleural mesothelioma DA Fennell, G Gaudino, KJ O'byrne, L Mutti, J Van Meerbeeck Nature clinical practice Oncology 5 (3), 136-147, 2008 | 158 | 2008 |
| Association of SV40 with human tumours B Jasani, A Cristaudo, SA Emri, AF Gazdar, A Gibbs, B Krynska, C Miller, ... Seminars in cancer biology 11 (1), 49-61, 2001 | 132 | 2001 |
| Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications L Sigalotti, S Coral, M Altomonte, L Natali, G Gaudino, P Cacciotti, ... British journal of cancer 86 (6), 979-982, 2002 | 124 | 2002 |
| Scientific advances and new frontiers in mesothelioma therapeutics L Mutti, T Peikert, BWS Robinson, A Scherpereel, AS Tsao, M de Perrot, ... Journal of Thoracic Oncology 13 (9), 1269-1283, 2018 | 115 | 2018 |
| SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study A Cristaudo, R Foddis, A Vivaldi, R Buselli, V Gattini, G Guglielmi, ... Cancer research 65 (8), 3049-3052, 2005 | 112 | 2005 |
| Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma A Sartore-Bianchi, F Gasparri, A Galvani, L Nici, JW Darnowski, ... Clinical Cancer Research 13 (19), 5942-5951, 2007 | 111 | 2007 |
| Estrogen receptor-β affects the prognosis of human malignant mesothelioma G Pinton, E Brunelli, B Murer, R Puntoni, M Puntoni, DA Fennell, ... Cancer research 69 (11), 4598-4604, 2009 | 105 | 2009 |
| SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure P Cacciotti, D Barbone, C Porta, DA Altomare, JR Testa, L Mutti, ... Cancer research 65 (12), 5256-5262, 2005 | 105 | 2005 |
| Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive … B Castagneto, S Zai, L Mutti, A Lazzaro, R Ridolfi, E Piccolini, A Ardizzoni, ... Lung Cancer 31 (2-3), 303-310, 2001 | 101 | 2001 |
| Targeting hypoxic response for cancer therapy E Paolicchi, F Gemignani, M Krstic-Demonacos, S Dedhar, L Mutti, ... Oncotarget 7 (12), 13464, 2016 | 100 | 2016 |
| HLA-B* 44 and C* 01 prevalence correlates with Covid19 spreading across Italy P Correale, L Mutti, F Pentimalli, G Baglio, RE Saladino, P Sileri, ... International journal of molecular sciences 21 (15), 5205, 2020 | 98 | 2020 |
